Back to top

immuno-therapy: Archive

Zacks Equity Research

Roche's Tecentriq Wins FDA Nod for Label Expansion in Bladder Cancer

RHHBY wins FDA approval for Tecentriq label expansion as a ctDNA-guided adjuvant therapy for bladder cancer patients at high risk of recurrence.

RHHBYNegative Net Change AMRNNegative Net Change IMCRPositive Net Change INDVNegative Net Change